Bomback, MD, MPH answers HCPLive’s questions regarding phase 3 VALIANT results and pegcetacoplan’s therapeutic ability in C3G and IC-MPGN.
Andrew Bomback, MD, MPH
Advertisement
Andrew Bomback, MD, MPH, is an assistant professor of medicine at Columbia University Medical Center.
Articles by Andrew Bomback, MD, MPH
A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis
2
Functional Cures for T1D: Insulin Independence Through Islet Transplantation
3
Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk
4
Monitoring Response and Setting Expectations: A Long-Term Partnership With Patients
5